Literature DB >> 17496556

Competing events influence estimated survival probability: when is Kaplan-Meier analysis appropriate?

David Jean Biau1, Aurélien Latouche, Raphaël Porcher.   

Abstract

The Kaplan-Meier estimator is the current method for estimating the probability of an event to occur with time in orthopaedics. However, the Kaplan-Meier estimator was designed to estimate the probability of an event that eventually will occur for all patients, ie, death, and this does not hold for other outcomes. For example, not all patients will experience hip arthroplasty loosening because some may die first, and some may have their implant removed to treat infection or recurrent hip dislocation. Such events that preclude the observation of the event of interest are called competing events. We suggest the Kaplan-Meier estimator is inappropriate in the presence of competing events and show that it overestimates the probability of the event of interest to occur with time. The cumulative incidence estimator is an alternative approach to Kaplan-Meier in situations where competing risks are likely. Three common situations include revision for implant loosening in the long-term followup of arthroplasties or implant failure in the context of limb-salvage surgery or femoral neck fracture.

Entities:  

Mesh:

Year:  2007        PMID: 17496556     DOI: 10.1097/BLO.0b013e3180986753

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  26 in total

1.  Are Hooded, Crosslinked Polyethylene Liners Associated with a Reduced Risk of Revision After THA?

Authors:  Adrian Bauze; Somen Agrawal; Alana Cuthbert; Richard de Steiger
Journal:  Clin Orthop Relat Res       Date:  2019-06       Impact factor: 4.176

2.  How to deal with lost to follow-up in total knee arthroplasty : a new method based on the competing risks approach.

Authors:  Klaas-Auke Nouta; Bart G Pijls; Marta Fiocco; J Christiaan Keurentjes; Rob G H H Nelissen
Journal:  Int Orthop       Date:  2013-12-05       Impact factor: 3.075

3.  CORR Insights(®): Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.

Authors:  Raphaël Porcher
Journal:  Clin Orthop Relat Res       Date:  2015-04-11       Impact factor: 4.176

4.  Editorial: Estimating survivorship in the face of competing risks.

Authors:  M Daniel Wongworawat; Matthew B Dobbs; Mark C Gebhardt; Terence J Gioe; Seth S Leopold; Paul A Manner; Clare M Rimnac; Raphaël Porcher
Journal:  Clin Orthop Relat Res       Date:  2015-02-11       Impact factor: 4.176

Review 5.  Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.

Authors:  Sarah Lacny; Todd Wilson; Fiona Clement; Derek J Roberts; Peter D Faris; William A Ghali; Deborah A Marshall
Journal:  Clin Orthop Relat Res       Date:  2015-11       Impact factor: 4.176

6.  Long-term survivorship of a monoblock long cementless stem in revision total hip arthroplasty.

Authors:  Yannick Herry; Anthony Viste; Hugo Bothorel; Romain Desmarchelier; Michel-Henri Fessy
Journal:  Int Orthop       Date:  2018-10-01       Impact factor: 3.075

7.  Early Subsidence Predicts Failure of a Cemented Femoral Stem With Minor Design Changes.

Authors:  Per-Erik Johanson; Martin Antonsson; Bita Shareghi; Johan Kärrholm
Journal:  Clin Orthop Relat Res       Date:  2016-10       Impact factor: 4.176

8.  Does competing risk analysis give useful information about endoprosthetic survival in extremity osteosarcoma?

Authors:  Reinhard Schuh; Alexandra Kaider; Reinhard Windhager; Philipp T Funovics
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

9.  Statistical analysis of arthroplasty register data.

Authors:  Jonas Ranstam; Otto Robertsson
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

10.  Peri-prosthetic fractures around tumor endoprostheses: a retrospective analysis of eighteen cases.

Authors:  Nicolas Barut; Philippe Anract; Antoine Babinet; David Biau
Journal:  Int Orthop       Date:  2015-07-28       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.